Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
Aflibercept biosimilars match the original drug for eye disease treatment
This systematic review and meta-analysis evaluated aflibercept biosimilars versus reference aflibercept for neovascular age-related macular …
A large review of 4064 patients found that aflibercept biosimilars work just as well as the original drug for two common eye conditions.
AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST
AI fluid measurements better predict vision loss than thickness in AMD
This randomized phase III trial in 290 eyes with neovascular AMD found that AI-based quantification of intraretinal and subretinal fluid vol…
AI-based fluid volume tracking explains more vision changes than standard thickness measurements in macular degeneration patients.
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
Radiotherapy plus anti-VEGF therapy increases vision loss risk for nAMD
This systematic review and meta-analysis evaluated radiotherapy combined with anti-VEGF therapy versus anti-VEGF monotherapy for neovascular…
Adding radiotherapy to anti-VEGF treatment for wet macular degeneration was linked to a higher risk of vision loss compared to anti-VEGF alo…
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
How often does scarring develop in treated macular degeneration eyes?
A systematic review and meta-analysis of 58 studies in anti-VEGF-treated nAMD eyes found subretinal fibrosis developed in approximately 10-1…
Scarring in treated macular degeneration eyes affects 10% to 15% within two years and up to half by five years, causing vision loss averagin…
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.